Strategy for Pre-Clinical Development of Active Targeting MicroRNA Oligonucleotide Therapeutics for Unmet Medical Needs

We present here an innovative modular and outsourced model of drug research and development for microRNA oligonucleotide therapeutics (miRNA ONTs). This model is being implemented by a biotechnology company, namely AptamiR Therapeutics, in collaboration with Centers of Excellence in Academic Institutions. Our aim is to develop safe, effective and convenient active targeting miRNA ONT agents for the metabolic pandemic of obesity and metabolic-associated fatty liver disease (MAFLD), as well as deadly ovarian cancer.

Automated summary

We propose an innovative approach to drug research and development for miRNA oligonucleotide therapeutics. This model involves collaboration between a biotechnology company, AptamiR Therapeutics, and Centers of Excellence in Academic Institutions. Our focus is on developing safe, effective, and convenient miRNA ONT agents for metabolic disorders and ovarian cancer.